Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide.


Dalbavancin is a lipoglycopeptide antibiotic in clinical development as a once-weekly treatment for serious infections. A total of 532 patients, consisting of 502 patients with skin and soft tissue infections requiring parenteral therapy and 30 patients with catheter-related bloodstream infections, was available for population pharmacokinetic analysis. The… (More)


Cite this paper

@article{Buckwalter2005PopulationPA, title={Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide.}, author={Mary Buckwalter and James A. Dowell}, journal={Journal of clinical pharmacology}, year={2005}, volume={45 11}, pages={1279-87} }